Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,570 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06835725 | Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer(ADAPT-25) | recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER |
| 1 |
| Jun 24, 2026 |
| clinicaltrials |
| NCT01594723 | A Study of LY2784544 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 2 | 110 | Eli Lilly and CompanyINDUSTRY | 9 | Jun 23, 2026 | clinicaltrials |
| NCT02489006 | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer(NEO) | active not recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 4 | Jun 23, 2026 | clinicaltrials |
| NCT03016338 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 51 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03991832 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors(SOLID) | active not recruiting | Phase 2 | 58 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04084717 | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04510636 | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06783140 | Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer(PLATINUM-CAN) | active not recruiting | Phase 2 / Phase 3 | 10 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06813079 | Using Tumor Models to Determine Treatments | recruiting | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07048743 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer(PEARL-C1) | recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02151084 | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | active not recruiting | Phase 2 | 57 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 6 | Jun 22, 2026 | clinicaltrials |
| NCT05843188 | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 155 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | active not recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT03768570 | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | active not recruiting | Phase 2 | 82 | Canadian Cancer Trials GroupNETWORK | 3 | Jun 18, 2026 | clinicaltrials |
| NCT07607925 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 / Phase 2 | 49 | GlaxoSmithKlineINDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT04317105 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | active not recruiting | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04702880 | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | completed | Phase 2 | 135 | Bristol-Myers SquibbINDUSTRY | 11 | Jun 17, 2026 | clinicaltrials |
| NCT00554372 | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 30 | Jennerex BiotherapeuticsINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 20 | GlaxoSmithKlineINDUSTRY | 8 | Jun 16, 2026 | clinicaltrials |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 383 | MedImmune LLCINDUSTRY | 11 | Jun 15, 2026 | clinicaltrials |
| NCT04262856 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer(ARC-7) | completed | Phase 2 | 151 | Arcus Biosciences, Inc.INDUSTRY | 7 | Jun 15, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | terminated | Phase 2 | 648 | Spectrum Pharmaceuticals, IncINDUSTRY | 8 | Jun 12, 2026 | clinicaltrials |
| NCT04566887 | Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 105 | University Health Network, TorontoOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07645118 | Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer(IMPERIA) | not yet recruiting | Phase 2 | 10 | Dr. Te VuongOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05754840 | CANnabinoids in Pediatric ONCology(CAN-PONC) | recruiting | Phase 1 / Phase 2 | 60 | University of ManitobaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06050707 | MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach(MAESTRO) | recruiting | Phase 2 | 80 | University Health Network, TorontoOTHER | 3 | Jun 10, 2026 | clinicaltrials |
| NCT07535905 | Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients(REVIVE) | not yet recruiting | Phase 2 | 96 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06167785 | A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T(ZeTA) | recruiting | Phase 2 | 76 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 218 | NRG OncologyOTHER | 4 | Jun 8, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT03839342 | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations(BEAVER) | active not recruiting | Phase 2 | 26 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT00107198 | Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease | completed | Phase 2 | 188 | Children's Oncology GroupNETWORK | 6 | Jun 5, 2026 | clinicaltrials |
| NCT01702831 | Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance(BuMelMCRN001) | completed | Phase 2 | 78 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | completed | Phase 1 / Phase 2 | 336 | Constellation PharmaceuticalsINDUSTRY | 9 | Jun 4, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07014137 | A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas | recruiting | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01415752 | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 373 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 3, 2026 | clinicaltrials |
| NCT02927912 | Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction | active not recruiting | Phase 2 | 108 | Ohio State University Comprehensive Cancer CenterOTHER | 2 | Jun 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials